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Abstract
This statement addresses a request to EFSA from the Dutch Ministry of Health, Welfare and Sport to
assess the impact of recent evidence underlying the conclusions of the 2016 RIVM report on the
temporary tolerable daily intake (t-TDI) for BPA of 4 lg/kg bw per day set by EFSA in 2015. The CEF
Panel has then evaluated the results of two studies published by Menard et al. in 2014, suggesting
food intolerance and impaired immune response to parasitic infection in rats exposed perinatally to
BPA doses in the lg/kg bw per day range. The same appraisal criteria and weight-of-evidence analysis
used for the 2015 EFSA opinion on BPA were applied to these studies. This new evidence adds to the
indications of immunotoxicity of BPA in animals reported in previous reviews. For the only endpoint for
which multiple BPA doses were tested (immunoglobulin G (IgG) levels), a benchmark dose analysis of
the dose–response data was carried out. Due to the high interanimal variability within the treatment
groups resulting in wide conﬁdence intervals and the limited dose–response, the CEF Panel concluded
that these data on anti-ovalbumin IgG antibodies are not suitable to derive a reference point for BPA
on immunotoxicity. Furthermore, the limitations identiﬁed in both the Menard et al. studies confound
the interpretation of the results and prevent the assessment of the relevance to human health. The
CEF Panel overall considers that the results from the two Menard et al. studies are not sufﬁcient to call
for a revision of the EFSA t-TDI for BPA. EFSA will start a review of all the scientiﬁc evidence published
after 2012 and relevant for BPA hazard assessment (including immunotoxicity) in 2017. The results of
immunological studies, such as the two evaluated here, would form a useful contribution to this
evaluation provided that the limitations identiﬁed herein were addressed.
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1. Introduction
1.1. Background and Terms of Reference as provided by the Dutch
Ministry of Health, Welfare and Sport
The Background and Terms of reference for this statement is provided in a letter sent to EFSA from
the Dutch Ministry of Health, Welfare and Sport on 19 April 2016 and stating the following:
‘Please ﬁnd enclosed the report “Bisphenol A, Part 2 Recommendations for Risk Management”
drawn up by the Dutch National Institute for Public Health and the Environment (RIVM). In this report,
the RIVM has made an assessment of environmental and health risks of bisphenol A (BPA) and
possible risk management measures. BPA is in many different products and has an effect on the
endocrine system.
In 2014 and 2015 European standards for safe exposure to BPA for workers and consumers are
strengthened. Recent scientiﬁc research shows that BPA can damage the immune system of the fetus
or young children at lower exposure levels than to which the current standards for BPA are based. This
lower level of exposure is at approximately the same level as the daily exposure of consumers and
workers to BPA. As a result of this exposure people have possibly more chance to develop food
intolerances and they can be more susceptible to infectious diseases.
The RIVM concludes that these new ﬁndings constitute sufﬁcient reason to consider further
tightening of standards and suggests to take additional measures at the short term, to further reduce
exposure to BPA.
I would kindly but urgently request you to carefully examine the results of the RIVM study and take
appropriate actions. The content of this report is an important addition to the existing knowledge
about BPA’.
1.2. Interpretation of the Terms of Reference
This statement only addresses the urgent request of the Dutch Ministry of Health, Welfare and
Sport ‘to carefully examine the results of the RIVM study’ (RIVM, 2016). Accordingly, the current
evaluation focuses only on the two studies by Menard et al. (2014a,b) on BPA immunotoxicity
underlying the conclusions of the RIVM report, leading RIVM to suggest a reconsideration of the EFSA
t-TDI.
2. Data and methodologies
2.1. Data
• Menard et al. (2014a) paper and original data
• Menard et al. (2014b) paper
2.2. Methodologies
The methodology used including the criteria and principles set for reviewing the experimental
studies and the weight of evidence (WoE) approach applied to hazard identiﬁcation, is the same as
that used in the EFSA opinion on BPA of 2015 (EFSA CEF Panel, 2015). This is described in detail in
Appendix A.
3. Assessment
3.1. Review of the two studies by Menard et al. (2014a,b)
3.1.1. Menard et al. (2014a) Food intolerance at adulthood after perinatal
exposure to the endocrine disruptor bisphenol A. The FASEB Journal, 28,
4893–4900
Menard et al. (2014a) studied multiple immune parameters to address the effects of exposure to BPA
on the response to dietary antigens. In the ﬁrst study, pregnant and lactating Wistar rats were treated
orally (most likely gavage but not further speciﬁed by the authors) with BPA (0.5, 5 or 50 lg/kg body
weight (bw) per day) or vehicle (4% ethanol in corn oil) for approximately 30 days from gestation day 15
until pup weaning at postnatal day (PND) 21.
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To evaluate the immune response to the food antigen ovalbumin (OVA), adult female offspring
from these dams were fed 20 mg OVA (tolerised) or bicarbonate buffer vehicle control (immunised) via
oral gavage on PND 45 (~ 6.5 weeks). All rats were given a subcutaneous (s.c.) injection of 100 lg
OVA on PND 52 (plus Complete Freund Adjuvant) and PND 66, and euthanised on PND 73
(10.5 weeks). Following this treatment, serum OVA-speciﬁc antibody levels were examined along with
splenic ex vivo proliferation and cytokine production following OVA stimulation.
BPA treatment at all doses signiﬁcantly increased anti-OVA immunoglobulin G (IgG) antibodies both
in OVA-immunised and OVA-tolerised animals as compared with animals without BPA exposure.
Irrespective of the BPA treatment, the tolerised rats had lower levels of OVA-speciﬁc IgG than their
immunised counterparts. The authors claimed a non-monotonic BPA dose–response relationship with
the highest antibody titres being observed for the 5 lg group (for both tolerised and immunised
animals). The isotype of IgG was not indicated and the authors stated that no increases in
immunoglobulin E (IgE) were observed.
Additional endpoints were evaluated in adult females following perinatal exposure to 5 lg BPA/kg
bw per day only. Ex vivo assays were conducted to assess multiple measures of cell responsiveness
and activation responses in splenic lymphocytes obtained from control and OVA-immunised/tolerised
animals exposed to BPA and following restimulation with OVA in vitro.
For the OVA-speciﬁc splenocyte proliferation, a signiﬁcant increase in cell proliferation was observed
for the BPA/tolerised rats as compared to the non-BPA-exposed counterpart. There were no changes in
proliferation between the BPA-treated and -untreated rats for the immunised group. A signiﬁcant
increase in interferon gamma (IFNc) production was observed for the BPA/immunised rats when
compared to the non-exposed immunised rats. This change was not observed for the tolerised rats. No
changes in interleukin (IL)-10 were observed for any group.
Immune phenotyping was conducted on splenocytes from PND 45 rats (these spleens were from
rats in a separate study that were not exposed to OVA). A signiﬁcant increase in activated splenocytes
was observed along with no change in regulatory T-cells following exposure to BPA when compared to
vehicle controls. This analysis was not conducted on OVA-tolerised/immunised rats.
A long-term OVA oral challenge was also conducted to explore physiological consequences of
developmental BPA exposure on food intolerance. Adult female offspring from dams treated with 5 lg
BPA/kg bw per day (from gestational day 15 to PND 21 as described above) were fed 20 mg OVA
(tolerised) or bicarbonate buffer vehicle control (immunised control) via oral gavage on PND 45,
immunised on PND 52 (s.c. injection of 100 lg OVA + Complete Freund Adjuvant), and received an
oral challenge via gavage with 50 mg OVA on PND 59, 61, 63, 65 and 67. The animals were
euthanised on PND 67 (9.5 weeks). Colon samples were evaluated for cytokine production and
myeloperoxidase (MPO) activity. Antibody levels were not evaluated to conﬁrm tolerance.
OVA-tolerised rats perinatally exposed to BPA had increased MPO activity and elevated
concentrations of the cytokines IL-10 and IFNc in colonic tissues as compared to the unexposed
counterpart. No changes were identiﬁed in the immunised rats. Levels of transforming growth factor
beta (TGFb) were signiﬁcantly decreased in both OVA-tolerised and OVA-immunised rats.
It was indicated that 7–26 female offspring/group were included for the studies described above.
In summary, the authors conclude that low-dose exposure to BPA induced the failure of oral
tolerance in adult life and colonic inﬂammation following oral challenge.
The strengths and weaknesses identiﬁed by the EFSA Panel on Food Contact Materials, Enzymes,
Flavourings and Processing Aids (CEF Panel) in this study are listed in Table 1.
Comments from the CEF Panel
The authors measured the critical cell populations, cytokines, immunoglobulins and MPO that
provide a mechanistic framework underlying the immune-speciﬁc response to food allergens and the
inﬂammatory response in the intestine using relevant models. There was some internal consistency in
this study supporting the biological plausibility of the ﬁndings.
The enhancement of OVA-speciﬁc IgG in the plasma of BPA-treated offspring may suggest a
dysregulation of antigen-speciﬁc tolerance in the gastrointestinal (GI) tract. However, looking at the
individual animal data, a high level of variability in the data set was observed. The study would beneﬁt
from additional controls including non-tolerised/non-immunised BPA controls and tolerised/non-
immunised controls. In the measurement of OVA-speciﬁc IgG where three doses were used, the
authors claim a non-monotonic dose–response curve, but no statistical support for this conclusion was
provided. No power calculation was presented and the number of animals per experimental group
varied substantially (n = 11–26 female offspring/group). The authors do not report on the allocation of
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the pups to the experimental groups and whether litter effects were controlled for. Neither was this
evident from the raw data. Also, the number of dams was not reported, and given the number of pups
used per group that of dams may have been as low as two or three per group.
Only spleen cells were evaluated for in vitro OVA restimulation and proliferation (information from
mesenteric lymph node (MLN) would be beneﬁcial). Cell proliferation was evaluated following 6 days of
OVA stimulation. However, cell viability was not reported.
The above ﬁndings may be supported by the observed increase in OVA-speciﬁc cell proliferation
in the BPA-exposed OVA-tolerised rats and the corresponding increase in the number of activated
T-lymphocytes in the spleens from these animals. However, a lack of the expected response in
immunised animals raises some doubts about the reliability of the increased cell proliferation reported
for the BPA-exposed groups. The authors evaluated speciﬁc endpoints in the GI tract including
cytokine and MPO production that suggest alterations in inﬂammatory responses in that organ, but no
conﬁrmatory pathology was provided.
It is a signiﬁcant limitation that the authors conducted the majority of their studies with only one
dose of BPA (5 lg/kg bw per day). The study would have been considerably strengthened if all of the
endpoints had been tested at multiple doses. BPA measurements in biological samples were not
performed. Overall, the paper lacks details in the study design and reporting. Assessment of only one
gender and use of an outbred strain (not stated by the authors but normally the Wistar strain is
outbred unless differently speciﬁed) limits interpretation of the ﬁndings. Some of the data (cytokines
and MPO) were inconsistent within the study. The lack of standard toxicological parameters (body and
organ weights and histology of the spleen, thymus and intestine) is an additional limitation of the
study.
Methods and statistics conducted for the ﬂow cytometry study were unclear, i.e. the number of
gated events and cells were not reported and it is unclear if the percentages reported reﬂect the total
number of cells or CD4+ cells). Immune phenotyping was not evaluated on OVA-tolerised/immunised
animals and this was only conducted on spleens (information from MLN would be beneﬁcial).
Although the Panel noted signiﬁcant limitations in this study, the reported alterations in endpoints
associated with food allergy and intolerance suggest there may be some potential immunotoxic effects
in rats associated with perinatal exposure to 5 lg BPA/kg bw per day.
3.1.2. Menard et al. (2014b). Perinatal exposure to a low dose of bisphenol A
impaired systemic cellular immune response and predisposes young rats
to intestinal parasitic infection. PLOS One, 9, e112752
Pregnant and lactating Wistar rats were treated orally (most likely gavage but not further speciﬁed
by the authors) with BPA (5 lg/kg bw per day) or vehicle (4% ethanol in corn oil) for approximately
30 days from gestation day 15 until weaning on PND 21.
To evaluate the immune response to dietary antigens in juvenile animals, female offspring from
these dams were fed by gavage 20 mg OVA (tolerised) or control bicarbonate buffer (immunised) on
PND 25 (~ 3.5 weeks). All rats were challenged on PND 32 (100 lg OVA s.c. injection + Complete
Freund Adjuvant) and PND 46 (100 lg OVA s.c.), and euthanised on PND 53 (7.5 weeks).
After this treatment, serum OVA-speciﬁc antibody levels were examined along with splenic and MLN
cytokine production following OVA stimulation.
Irrespective of BPA treatment, OVA-speciﬁc IgG titres were lower in tolerised than in immunised
rats. Perinatal exposure to 5 lg BPA/kg bw per day did not affect the anti-OVA IgG antibodies either in
immunised or tolerised animals. The isotype of IgG was not indicated and the authors stated that no
increases in IgE were observed.
Ex vivo assays were conducted to assess multiple measures of cell responsiveness and activation
responses in spleen and MLN cells obtained from control and OVA-immunised/tolerised animals
exposed to BPA and following in vitro OVA restimulation. It was indicated that for these studies 12–17
female offspring were included per group.
Splenocytes from the BPA/immunised and BPA/tolerised rats produced reduced amounts of IFNc as
compared to cells obtained from the non-BPA-exposed counterparts. A similar BPA-induced decrease in
IFNc production was observed only in MLN cells obtained from OVA-immunised animals, and not in
cells from OVA-tolerised animals. No changes in IL-10 were observed in the spleen or mesenteric
lymph node.
Immune phenotyping was conducted on splenocytes from PND 25 rats (these spleens were from
rats that were not exposed to OVA). A signiﬁcant decrease in regulatory T-cells, T-helper cells (which
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also were composed of T-regs) and dendritic cells was observed following exposure to BPA in the
spleen and MLN compared to vehicle controls. This analysis was not conducted on OVA-tolerised/
immunised rats. It was indicated that 12 female offspring were included per group for the studies
described above.
Host resistance to the helminthic parasite Nippostrongylus brasiliensis following developmental
exposure (from gestational day 15 to PND 21 as described above) to 5 lg BPA/kg bw per day was
also evaluated. At PND 25, female offspring were infected with 1,000 infective stage larvae
N. brasiliensis subcutaneously and euthanised 1 week later (PND 32). Colon samples were evaluated
for cytokine production, MPO activity and living larvae.
While there was an increase in IgE following infection, there was no difference in response to BPA
exposure.
Rats perinatally exposed to BPA had elevated levels of living larvae in their faecal material as
compared to controls. This was accompanied by a signiﬁcant decrease in MPO activity and elevated
levels of cytokines (IL-4 and IL-13 (TH2), IL-10 (anti-inﬂammatory) and growth-regulated oncogene/
keratinocyte chemoattractant (GRO/KC), and IFNc (pro-inﬂammatory)) in the small intestine as
compared to the non-BPA-exposed infected animals.
It was indicated that 7–8 female offspring were included per group for the studies described above.
In summary, the authors conclude that in juvenile rats, low-dose perinatal exposure to BPA resulted
in normal responses to food antigen but failed to induce a proper cellular immune response following
systemic immunisation and suggest an immunosuppressive effect. In addition, they report a decreased
host resistance in juvenile rats following perinatal BPA exposure.
The strengths and weaknesses identiﬁed by the CEF Panel in this study are listed in Table 1.
Comments from the CEF Panel
The authors measured the cell populations, cytokines, immunoglobulins and MPO that provide a
mechanistic framework underlying the immune-speciﬁc response to an antigen and parasitic infections
using relevant models. There was some internal consistency in this study supporting the biological
plausibility of the ﬁndings. Lack of enhancement of OVA-speciﬁc IgG in the plasma suggests no effect
on antigen-speciﬁc tolerance in the GI tract, but in the disease-resistant model, the authors report an
increase in the number of larvae in faeces and signiﬁcant decrease in MPO following infection in BPA-
exposed female offspring.
It is a signiﬁcant limitation that the authors conducted these experiments using only one dose of
BPA (5 lg/kg bw per day). The ﬁndings would have been considerably strengthened if all of the
endpoints had been tested at multiple doses. The authors do not report on the allocation of the pups
to the experimental groups and whether litter effects were controlled for. Also, the number of dams
was not reported, and given the number of pups used per group, that of dams may have been as low
as two or three per group. The study overall lacks details in the study design and report. Assessment
of only one gender and use of outbred strain (not stated by the authors but normally the Wistar strain
is outbred unless differently speciﬁed) limits interpretation of the ﬁndings. The lack of standard
toxicological parameters (body and organ weights and histology of the spleen, thymus and intestine) is
a limitation of the study.
Methods and statistics conducted for the ﬂow cytometry study are unclear (i.e. number of gated
events not reported, number of cells not reported and if the percentages reported reﬂect total number
of cells or CD4+ cells). Given the small increase in the living larvae and the large variation in these
data for the host resistance model, the biological signiﬁcance of this result is considered questionable.
3.2. Weight of evidence of the immune effects of BPA
In the 2015 EFSA opinion, a WoE analysis was performed for each toxicological endpoint including
the immune effects. In particular, whether BPA induces immune effects was considered using a tabular
format for weighing different lines of evidence. The overall outcome of this WoE evaluation is
presented in the conclusions on the immune effects taken from the 2015 EFSA opinion and reported
below.
‘Based on recent human studies, there are indications that BPA may be linked to immunological
outcomes in humans, although these studies had limitations and confounding factors may have
been present. A causal link between BPA exposure during pregnancy or in childhood and the
immune effects in humans cannot be established.
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Studies in animals lend support to the possibility of immunological effects of BPA. Most of these
studies suffered from shortcomings in experimental design and reporting. Although dose-responses
could not be conﬁdently established in most studies, a dose-related effect was observed in allergic
lung inﬂammation.
Using a WoE approach, the CEF Panel assigned a likelihood level of “-as likely as not- to likely” to
immunotoxic effects of BPA. Since the likelihood level for this endpoint is less than “likely” (see
Appendix A of EFSA CEF Panel, 2015), this endpoint was not taken forward for assessing the
toxicological reference point, but was taken into account in the evaluation of uncertainty for hazard
characterisation and risk characterisation (Section 4.3 of EFSA CEF Panel, 2015).’
The CEF Panel had already included the study by Bauer et al. (2012) in its 2015 WoE analysis of
animal studies and reviewed it as follows:
‘The CEF Panel notes that also the study by Bauer et al. (2012) indicated enhancement of
ovalbumin-induced allergic responses, notably inﬂammation, by oral exposure to BPA, and that a
dose-dependence was evident. The CEF Panel also noted that in this latter study the inﬂammation
noted was seen in females but not males. It should be mentioned that elevated immune responses
in female humans as well as female animals have been reported previously, including innate
responses, cytokine responses and vaccine responses (Klein et al., 2010; McLelland and Smith,
2011; Hochstenbach et al.,2012).’
For the present statement, the CEF Panel took the 2015 WoE evaluation carried out on animal
studies on the immune effects (EFSA CEF Panel, 2015) as the starting point and assessed whether the
two Menard et al. studies from 2014 have an impact on the overall outcome of the WoE analysis (see
Table 1). No additional literature has been searched for in the public domain,1 since a review of all the
scientiﬁc evidence published after 2012 and relevant for BPA hazard assessment (including BPA
immunotoxicity) will start next year. This will follow a protocol currently under development which will
deﬁne a priori the strategy for collecting, appraising, analysing and integrating the relevant evidence.
The strengths and weaknesses identiﬁed by the Panel in the two new Menard et al. studies are
listed in the left hand side column of the WoE table (Table 1). The second column reports the
(positive) answer to the question ‘Is BPA immunotoxic in animals?’ as reported by the study authors.
Taking into consideration all the strengths and weaknesses of each study, the Panel assigned to the
new evidence a low score for reliability (third column) and a limited inﬂuence (/↑, see Table A.4 in
Appendix A for an explanation of the symbols used for expressing the weight of each new line of
evidence) on the likelihood of a positive answer to the question (fourth column).
After considering the individual inﬂuences of the two new lines of evidence and the starting point
the Panel concluded that evidence from the new studies adds to the indications of immunotoxicity of
BPA in animals reported in previous reviews. However, uncertainties in the dose–response, the study
conduct and design, along with a high variability in the observed responses, lower the conﬁdence in
the data as presented.
Overall, the CEF Panel reconﬁrmed the overall conclusion already expressed in 2015 of a likelihood
level of ‘from -as likely as not (ALAN)- to likely’ (see Table A.2 for standard terms used for expressing
the overall likelihood in the WoE tables) for BPA immunotoxic effects in animals.
1 The CEF Panel was aware of the RIVM Expert Workshop report (in press) by Hessel EVS et al., Assessment of recent
developmental immunotoxicity studies with bisphenol A in the context of the 2015 EFSA t-TDI, Repro Toxicol 2016; Available:
http://dx.doi.org/10.1016/j.reprotox.2016.06.020. The present EFSA statement, however, addresses the RIVM report (RIVM,
2016) sent by the Ministry of Health that was speciﬁcally referred to in the Terms of Reference received by EFSA.
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3.3. Benchmark dose (BMD) analysis of the dose–response data by
Menard et al. (2014a)
In compliance with the draft update of the guidance of the Scientiﬁc Committee on the use of the
benchmark dose approach in risk assessment (EFSA Scientiﬁc Committee, 2016, under public
consultation until 20 September 2016), the results on OVA-speciﬁc IgG titres obtained in the food
tolerance study with BPA (Menard et al., 2014a) have been submitted to statistical dose–response
modelling. The results obtained are reported in detail in Appendix B.
The data point within each treatment group for the tolerised mice shows high variability. As
recommended by the EFSA Scientiﬁc Committee (2016), ‘one might consider selecting a benchmark
response (BMR) higher than 5% for endpoints that tend to show a relatively large within-group
variation (EFSA Scientiﬁc Committee, 2016)’. The EFSA Scientiﬁc Committee also recommends to
deﬁne the BMR as a per cent change in the mean response as compared to the background response.
However, although a paper describing an approach to accomplish this has been submitted for
publication (Slob, 2016), as yet no full reporting of this strategy is available, and appreciation of its
consequences is not possible. Therefore, BMD modelling was only performed for the default BMR of
5% extra risk for IgG titres in both OVA-tolerised and OVA-immunised animals (for further details see
Appendix B.1).
Due to the high interanimal variability within the treatment groups and limited dose–response
resulting in high conﬁdence intervals, the CEF Panel concluded that the data was not suitable to derive
a reference point for BPA on immunotoxicity. This conclusion was not altered when the Panel also tried
to perform the BMD modelling using a much higher BMR (700%, derived on the basis of the strategy
as outlined by Slob in 2016).
3.4. Discussion on the outcome of the Menard et al. (2014a,b) studies
In the two Menard et al. (2014a,b) studies, the authors reported potential age- and organ-speciﬁc
effects of perinatal BPA exposure. The Panel noted that the results of the two papers do not support
each other due to differences with regard to start of immune protocols and outcomes. Overall, the
results further conﬁrm that the immune system is a potential target for BPA. However, because of the
limitations of the studies identiﬁed by the Panel, the ﬁndings do not call for a revision of the outcome
of the previous WoE evaluation of the immune effects (from ALAN to likely) in the 2015 EFSA opinion
(EFSA CEF Panel, 2015).
Our current understanding of the immune processes associated with the development of oral
tolerance still has many gaps. However, the basic mechanisms are fairly well understood and are
similar in the rodent and human. The authors have examined many endpoints associated with the
known mechanisms that contribute to this response. Exposure to BPA in the perinatal period altered
several immune processes that either regulate or are a manifestation of the immune response in the
gastrointestinal tract. Food allergies in children have signiﬁcantly increased in recent years and
numerous authors have suggested that changes in the environment are more likely responsible for the
enhanced allergy prevalence than genetic shifts.
The cells and soluble mediators that are involved in the immune response to parasitic infection are
generally similar in rodents and humans, manifesting as a TH2 type response with an innate immune
component. However, the speciﬁc aspects of the response that result in clearance are organism
speciﬁc. The nematode N. brasiliensis is a rodent-speciﬁc pathogen. While the life cycle and
immunological host response for N. brasiliensis is similar to that observed in humans following infection
with helminthic pathogens, such as hookworms, the parallels are not exact. Although helminth
diseases are well-controlled in developed countries, they remain a signiﬁcant cause of morbidity in
poorer countries where sanitation and access to healthcare are limited.
Thus, the indication that BPA at a perinatal exposure of 5 lg/kg bw per day may have the potential
to alter the development of oral tolerance and susceptibility to parasitic infection in rodents is
considered a cause for concern and warrants for further examinations.
4. Conclusions
Evidence from the new Menard studies adds to the indications of potential immunotoxicity of BPA in
animals already reported by EFSA in 2015.
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Due to the high interanimal variability within the treatment groups resulting in high conﬁdence
intervals and limited dose response, the CEF Panel concludes that the data on anti-OVA IgG antibodies
in the Menard et al. study (2014a) are not suitable to derive a reference point for BPA on
immunotoxicity. Furthermore, the limitations of both Menard et al. studies observed by the
Panel confound the interpretation of the study results and therefore prevent the assessment of the
relevance to human health.
The CEF Panel overall considers that the results from the two Menard et al. studies are not
sufﬁcient to call for a revision of the t-TDI set in EFSA’s opinion on BPA from 2015.
EFSA will start a review of all the scientiﬁc evidence published after 2012 and relevant for BPA
hazard assessment (including immunotoxicity) in 2017. The results of immunological studies, such as
the two evaluated here, would form a useful contribution to this evaluation provided that the
limitations identiﬁed herein were addressed.
Documentation provided to EFSA
1) The original data from the study by Menard et al. (2014a) were kindly provided by Sandrine
Menard on 8 July 2016.
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Abbreviations
ALAN as likely as not
BMD benchmark dose
BMDL 95% lower conﬁdence limit (single-sided) of the benchmark doses
BMDU 95% upper conﬁdence limit (single-sided) of the benchmark doses
BMR benchmark dose response
BPA bisphenol A
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bw body weight
CEF EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
GI gastrointestinal
GRO/KC growth-regulated oncogene/keratinocyte chemoattractant
GUI-mode graphical user interface mode
IFNc interferon gamma
IgG immunoglobulin G
IL-4 interleukin 4
IL-13 interleukin 13
i.p. intraperitoneal
MLN mesenteric Lymph Node
MPO myeloperoxidase
OECD Organisation for Economic Co-operation and Development
OVA ovalbumin
PND postnatal day
RIVM Dutch National Institute for Public Health and the Environment
s.c. subcutaneous
t-TDI temporary tolerable daily intake
TH T helper
WoE weight of evidence
WG working group
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Appendix A – Detailed methodology for the study review and the weight of
evidence approach
A.1. Criteria and principles applied for assessing the strengths and
weaknesses of animal studies
The criteria applied for reviewing the studies are listed in Table A.1. The appraisal of the strengths and
weaknesses of the two studies was performed individually by three reviewers from the working group
(WG) on BPA immunotoxicity and their evaluations were presented and discussed at a WG meeting.
Table A.1: Criteria applied to assess the strengths and weaknesses of animal studies
Criteria
Interpretation/assessment
Comments
Strengths Weaknesses
Test substance identiﬁcation
Vehicle – Vehicle not reported
Test organism characterisation
Species and strain of the
animal
– Animal species and/or
strain not reported
Is the age and body weight
of the test organisms given?
– Animal age and/or body
weight not reported
Is the sex of the test
organism given?
– Sex of the animals tested
not reported
Study design description
Use of a priori study protocol/
study plan
– Lack of a priori study
protocol or study plan
Sample size – power of the
study (number of animals)
Large sample size Small sample size This is based on expert
judgement
Control procedures (were
negative and/or positive
controls included where
required)?
Both na€ıve controls and
vehicle controls available
Adequate positive
controls included (if
appropriate)
No vehicle controls were
tested
Number of BPA doses ≥ 3 dose levels tested Single dose level study Not mentioned as a
strength or weakness if
two dose levels were
tested
BPA dose levels Too wide dose spacing
*Too high dose levels
tested
Wide dose spacing makes
the study inadequate to
study a dose–response
relationship
Testing of BPA at very
high-dose levels is not
informative of effects
occurring at current
human exposure levels
BPA exposure assessment – Feed consumption (BPA
given by the diet) not
measured
BPA concentration and
homogeneity in the feed
mixture not guaranteed
analytically (BPA given by
the diet)
Drinking water
consumption (containing
BPA) not measured
The exact BPA doses
received by the animals
cannot be established
BPA Immunotoxicity
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Criteria
Interpretation/assessment
Comments
Strengths Weaknesses
Route and type of
administration/administration
scheme
Oral administration via
gavage (except for
neurobehavioural studies)
Maternal administration
via i.p. injection during
pregnancy
Not mentioned if: BPA
was given via diet or
drinking water and food/
water consumption was
measured; BPA was given
via s.c. injection; Maternal
dosing via i.p. injection
during pregnancy was
considered as a weakness
due to uncertain fetal
dosing
Oral administration via
gavage was considered as
a strength due to exact
dosing: only exceptions
were neurobehavioural
studies addressing
anxiety-like behaviours
due to animal handling
Frequency and duration of
exposure: Are frequency and
duration of exposure as well
as time-points of observations
explained?
– Single acute dose
administration (depending
on the endpoint)
Acute exposure is not
representative of human
exposure which is
prolonged in time
BPA exposure assessment BPA measurement in
biological samples
The quality of the analysis
is also checked
Test performance Test performed in one
sex only
Low number of animals
tested (in a test)
Blind treatment Blind treatment or Blind
evaluation of samples. . ..
– Blind treatment was
considered as a strength
if reported, and was not
mentioned if not
reported
Study results documentation/Study reporting
Study reporting – Insufﬁcient study
reporting (give details)
Details, e.g. number of
animals tested for each
test unclear or not
reported, time points
unclear, dose levels, etc.
Statistical analysis – Inappropriate statistics
(give details)
Details, e.g. litter effect
not considered,
inappropriate analysis
Plausibility of the study design and results
Is the study design chosen
appropriate for obtaining the
substance-speciﬁc data aimed
at?
– Study design not
appropriate to the scope
Diet Phytoestrogen-free diet
(e.g. soy free diet) or
feed content of
oestrogens negligible at
E-screen
Animal diet and
phytoestrogen content
not reported (or poorly
described)
Confounding by diet
BPA Immunotoxicity
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A.2. WoE approach
The CEF Panel applied a WoE approach to assess the overall likelihood (using the terms as in
Table A.2) of the association between BPA exposure and the immunotoxic effects in animals.
A tabular format (Table A.3) was used to facilitate the consistent treatment of the whole body of
evidence and transparently document the WoE analysis.
Criteria
Interpretation/assessment
Comments
Strengths Weaknesses
Housing conditions/
environmental contamination
Use of non-polycarbonate
cages, and of non plastic
(e.g. glass) or BPA-free
water bottles
Use of polycarbonate
cages and plastic water
bottles
OR
Type of cages and
drinking bottles not
reported
Confounding by
environmental
contamination
Quality assurance principles
GLP/other quality assurance
system
Study/analysis performed
under GLP or XX quality
assurance system
–
Protocol according to existing
guidelines, e.g. OECD
guidelines or EU guidelines
(or other e.g. national
guidance)
Study/test performed
according to XX
guidelines
–
Others On a case-by-case basis On a case-by-case basis This is based on expert
judgement
BPA: bisphenol A; GLP: good laboratory practice; OECD: Organisation for Economic Co-operation and Development.
*’Too high dose levels’ is an exclusion criterion for the studies on reproductive and developmental toxicity, and therefore, this
weakness is reported only for non-reproductive toxicity studies.
Table A.2: Set of standard terms used for expressing the overall likelihood in the WoE tables
(adapted from Mastrandrea et al., 2010)
Likelihood
Very likely
Likely
From -as likely as not (ALAN)- to likely
As likely as not (ALAN)
From unlikely to -as likely as not (ALAN)-
Unlikely
Very unlikely
WoE: weight of evidence.
BPA Immunotoxicity
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The conclusions of earlier assessments of BPA by EFSA in 2015 were taken as the starting point for
the new evaluation.
To draw its conclusion for each association question, the CEF Panel ﬁrst summarised the strengths
and weaknesses of each line of evidence and 2015 assessments in an overall reliability assessment
(expressed qualitatively on a scale of low, medium or high) and expressed it in terms of weight or
inﬂuence on the likelihood of a positive answer to each question, when considered independently of
the other lines of evidence (see Table A.4).
Taking into account the individual inﬂuences of all the lines of evidence and the starting point, the
CEF Panel expressed its conclusions in terms of the overall likelihood of a positive answer to the
question on the causal association between BPA exposure and the selected immunotoxic endpoint
using a scale of likelihood categories spanning from ‘Very unlikely’ to ‘Very likely’ (Table A.2). On this
scale ‘As likely as not’ means a level of likelihood between ‘Unlikely’ and ‘Likely’, where it is about
equally likely that BPA causes, or does not cause, the effect.
The approach described above is generically summarised in Table A.3.
The CEF Panel found it helpful to include separate columns in Table A.3 summarising steps in the
evaluation of each line of evidence.
The second column indicates the answer to the question as reported by the study authors (e.g. a
positive, negative or uncertain answer to the question), i.e. before the CEF Panel assessed strengths
and weaknesses.
The third column gives the CEF Panel’s assessment of the reliability based on the evaluation of the
strengths and weaknesses of each line of evidence, expressed qualitatively on a scale of low, medium
or high. A low score for reliability does not necessarily imply a poor quality study: e.g. it may relate to
a well-conducted study with results not reaching statistical signiﬁcance, but the treatment groups are
not large enough to be statistically conﬁdent there is no effect. The CEF Panel did not use a ﬁxed
formula to assess reliability of a study from its number of strengths and weaknesses, because this
would not take appropriate account of the varying weights of different strengths and weaknesses.
Instead, the reliability of the evidence as well as the inﬂuence on likelihood were agreed based on
collective expert judgement at the WG and CEF Panel meetings.
The evaluation of the weight or inﬂuence of each line of evidence was then recorded in the right
hand column using a deﬁned set of symbols (see Table A.4).
Table A.3: Example of table used in the WoE approach
Question 1: Is BPA. . .. . .. . .. . .. . .. . .. . ...?
Answer to the
question as reported
by the study authors
Reliability of
evidence
Inﬂuence on
likelihood
Starting point based on previous
assessments (EFSA, 2006; 2010; 2015):
(summarise conclusions of previous
assessments relating to this question)
Positive, negative or
uncertain
Low, medium or
high
See Table A.4
for key to
symbols
Line of Evidence 1: new evidence on . . .. . .. . ..
Strengths:
Weaknesses:
Line of Evidence 2: increased effect on. . .. . .
Strengths:
Weaknesses:
Overall conclusion on likelihood: Chosen
likelihood level
(see Table A.2)
BPA: bisphenol A; WoE: weight of evidence.
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The number (from one to three) of upward and downward arrows indicates the degree (small,
medium and high) of the impact of the new evidence to increase or decrease, respectively, the
likelihood of a positive answer to the question. In developing its judgment on the inﬂuence or weight
of each line of evidence, the CEF Panel took into account all the strengths and weaknesses it identiﬁed
in the left hand column of the WoE table.
The ‘dot’ is used when the reliability of the new line of evidence is considered as insufﬁcient as to
have an impact on the likelihood of a positive answer to a question. When the evidence base was too
weak to make a ﬁrm judgement about the inﬂuence, a range of symbols was given to reﬂect that
additional uncertainty. For example, /↑ indicates between negligible and minor positive inﬂuence on
likelihood.
A conclusion on the overall likelihood that BPA exposure was associated with a particular effect in
animals was expressed in the bottom row of the WoE table (Table A.3) both as a narrative statement
and using the likelihood terms as in Table A.2. Such conclusion was drawn after considering the
individual inﬂuences of all the lines of evidence and the starting point by expert judgement after a
thorough discussion at a WG and/or CEF Panel meeting level, and not by any standardised
combination of scores for reliability and inﬂuence, which would be simplistic and preclude the
consideration of other factors.
It is also important to emphasise that the likelihood assessed by the WoE approach refers
speciﬁcally to hazard identiﬁcation, i.e. it refers to the likelihood of an association between BPA and
the effect under consideration. It does not refer to the likelihood or frequency of the effect actually
occurring in humans, which depend on additional factors including the dose–response relationship for
the effect and the levels of human exposure to BPA.
Table A.4: Deﬁnition of symbols used for expressing the inﬂuence on likelihood of each line of
evidence in the WoE tables
Symbols Interpretation
↑ Minor contribution to increasing likelihood
↑↑ Moderate contribution to increasing likelihood
↑↑↑ Major contribution to increasing likelihood
↓ Minor contribution to decreasing likelihood
↓↓ Moderate contribution to decreasing likelihood
↓↓↓ Major contribution to decreasing likelihood
 Negligible inﬂuence on likelihood
WoE: weight of evidence.
Pairs of symbols indicate uncertainty about the inﬂuence, e.g. /↑ = between negligible and minor positive inﬂuence on
likelihood.
BPA Immunotoxicity
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Appendix B – Dose–response modelling of bisphenol A on immunotoxicity
In compliance with the draft update of the guidance of the Scientiﬁc Committee on the use of the
benchmark dose approach in risk assessment (EFSA Scientiﬁc Committee, 2016, under public
consultation until 20 September 2016), the results on OVA-speciﬁc IgG titres obtained in the food
tolerance study with BPA (Menard et al., 2014a) have been submitted to statistical dose–response
modelling. This study has been summarised in Section 3.3 of the main document.
For all modelling the R version 3.2.2 and the statistical package PROAST (version 61.6) has been
used in graphical user interface mode (GUI-mode). This package is available via: http://www.rivm.nl/
en/foodnutritionandwater/foodsafety/proast.jsp; the version mentioned can be requested directly from
the authors. Using this statistical package, 95% lower conﬁdence limit (single-sided) of the benchmark
doses (BMDLs) were calculated (see EFSA Scientiﬁc Committee, 2016) for the various effects. For the
evaluation, the statistical models available in PROAST for continuous data (i.e. the Exponential and Hill
families of models) were used.
B.1. Consideration of the use of the default BMR of 5% for continuous
data
The data point within each treatment group for the tolerised mice shows high variability (see
Table B.1 below). As recommended by the EFSA Scientiﬁc Committee of EFSA, ‘one might consider
selecting a BMR higher than 5% for endpoints that tend to show a relatively large within-group
variation (EFSA Scientiﬁc Committee, 2016)’. The EFSA Scientiﬁc Committee also recommends to
deﬁne the benchmark response (BMR) as a per cent change in the mean response as compared to the
background response. However, although a paper describing an approach to accomplish this has been
submitted for publication (Slob, 2016), as yet no full reporting of this strategy is available and
appreciation of its consequences is not possible. Therefore, BMD modelling was only performed for the
default BMR of 5% extra risk for IgG titres in both OVA-tolerised and OVA-immunised animals.
The dose–response modelling was carried out using individual data on OVA-speciﬁc IgG titres in
OVA-tolerised or OVA-immunised rats as provided by the study author. The data used are presented in
Table B.1.
B.2. Parameters used for BMD calculation (settings within PROAST)
The evaluations were carried out for female rats (the only sex used in the experiment) with the
following settings:
• BMR of 5% extra risk for continuous data on both immunised and tolerised animals.
• No restrictions for model parameters to limit, e.g. steepness of the ﬁtted dose–response curves
(default option).
• For all evaluations, the following criteria were used to decide on acceptability of modelling
output.
• For continuous variables, the model selected from the Exponential and Hill nested model
families was the model with the lowest loglikelihood from either the minimal or maximal
model.
It is noted that although the data in this table reﬂect measurements on individual animals no litter
data was provided. Therefore, the BMDL modelling could not take the possible litter effect into
account.
BPA Immunotoxicity
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B.3. BMD modelling of the IgG response in OVA-tolerised and
OVA-immunised rats
For continuous responses, the Hill and Exponential nested model families are applicable. In GUI-
mode, PROAST has two options for dose–response modelling: either selection of the minimal or
maximal model. The minimal model is used as recommended in the updated EFSA draft guidance on
BMD modelling (EFSA Scientiﬁc Committee, 2016). Note that the BMDL and 95% upper conﬁdence
limit (single-sided) of the benchmark doses (BMDU) values may come from different models.
BMD modelling in OVA-tolerised rats
Figure B.1 gives the graphical representation of the ﬁtted dose–response curves for the IgG titres
in OVA-tolerised rats using a BMR of 5%. The BMD modelling with minimal and maximal model was
similar. The outcome from the BMD modelling is shown below (Table B.2).
BMD modelling in OVA-immunised rats
Figure B.2 gives the graphical representation of the ﬁtted dose–response curves for the IgG titres
in OVA-immunised rats using a BMR of 5%. Only the maximal model gave an estimate on BMDL as
shown below (Table B.3).
Figure B.1: Dose–response modelling on IgG titres in OVA-Tolerised female rats perinatally exposed
to various doses of BPA using a BMR of 5%
Table B.2: Outcome of the BMD modelling on IgG titres in OVA-Tolerised female rats
Model
No of
parameters
loglik BMDL05 (µg/kg bw per day) BMDU05 (µg/kg bw per day)
Exponential Hill Exponential Hill Exponential Hill
Model 3 4 158.47 158.38
Model 5 5 158.57 0.000001 0.000001 0.5452 0.5447
Full model 5 158.36
BMD: benchmark dose; BMDL05: Benchmark dose lower conﬁdence interval when the percent change in mean response is 5%;
BMDU05: Benchmark dose upper conﬁdence interval when the percent change in mean response is 5%; IgG: immunoglobulin G;
OVA: ovalbumin.
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B.4. Conclusions on the BMD modelling of the IgG response
Due to the high interanimal variability within the treatment groups and limited dose–response
resulting in high conﬁdence intervals, the CEF Panel concluded that the data was not suitable to derive
a reference point for BPA on immunotoxicity. This conclusion was not altered when the Panel also tried
to perform the BMD modelling using a much higher BMR (700%, derived on the basis of the strategy
as outlined by Slob in 2016).
Figure B.2: Dose–response modelling on IgG titres in OVA-immunised female rats perinatally exposed
to various doses of BPA using a BMR of 5%
Table B.3: Outcome of the BMD modelling on IgG titres in OVA-immunised female rats
Model
No of
parameters
loglik BMDL05 (µg/kg bw per day) BMDU05 (µg/kg bw per day)
Exponential Hill Exponential Hill Exponential Hill
Model 3 4 96.72 96.75
Model 5 5 95.89 0.000001 0.000001 4.778 4.745
Full model 5 95.82
BMD: benchmark dose; BMDL05: Benchmark dose lower conﬁdence interval when the percent change in mean response is 5%;
BMDU05: Benchmark dose upper conﬁdence interval when the percent change in mean response is 5%; IgG: immunoglobulin G;
OVA: ovalbumin.
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